DelveInsight has launched a report on “Interstitial Cystitis Epidemiology Forecast to 2030”
DelveInsight’s ‘Interstitial Cystitis Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Interstitial Cystitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- According to DelveInsight, the total prevalent population of Interstitial Cystitis in the Seven Major Markets was approximately 8,517,779 in 2017.
- In the epidemiology model, the analystsreported a higher prevalence of Interstitial Cystitis the United States with around 5,000,101 prevalent cases in 2017.
- Among the European countries, Germany had the highest prevalent population of Interstitial Cystitis with 844,367 cases.
- Spain had the lowest prevalent population of 4,95,983 in 2017.
“As per DelveInsight’s analysis, the estimates suggest higher prevalence of the disease among the females throughout the 7MM”
According to the Urology Care Foundation, Interstitial cystitis/bladder pain syndrome (BPS) is a chronic bladder health issue. It is a feeling of pain and pressure in the bladder area. Along with this pain occurs in the lower urinary tract, which last for more than 6 weeks, without having an infection or other clear causes. It is a chronic, or long-lasting condition that causes painful urinary symptoms.
According to Interstitial Cystitis Association, currently here are two recognized subtypes of Interstitial cystitis: Non ulcerative and Ulcerative.
The exact cause of the disease is not known, but there are certain theories, such as a defect in the bladder tissue, which may allow irritating substances in the urine to penetrate the bladder, a specific type of inflammatory cell, called a mast cell. This cell releases histamine and other chemicals that lead to IC/BPS symptoms, changes in the nerves that carry bladder sensations, so pain is caused by events that are generally not painful, the body’s immune system attacks the bladder which is similar to other autoimmune conditions.
The symptoms include pain in pelvis or between the vagina and anus in women, and between the scrotum and anus in men (perineum), along with chronic pelvic pain, a persistent, urgent need to urinate, frequent urination—often of small amounts—throughout the day and night (up to 60 times a day), pain or discomfort while the bladder fills, and relief after urinating.
- The Interstitial Cystitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Interstitial Cystitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Interstitial Cystitis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Interstitial Cystitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Interstitial Cystitis
- The report provides the segmentation of the Interstitial Cystitis epidemiology
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Interstitial Cystitis?
- What are the key findings pertaining to the Interstitial Cystitis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
- What would be the total number of patients of Interstitial Cystitis across the 7MM during the forecast period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
- What is the disease risk, burden and unmet needs of the Interstitial Cystitis?
- What are the currently available treatments of Interstitial Cystitis?
- The Interstitial Cystitis Epidemiology report will allow the user to –
- Develop business strategies by understanding the trends shaping and driving the global Interstitial Cystitis market
- Quantify patient populations in the global Interstitial Cystitis market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Interstitial Cystitis therapeutics in each of the markets covered
- Understand the magnitude of Interstitial Cystitis population by its epidemiology
- The Interstitial Cystitis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Related Reports:
Interstitial Cystitis – Pipeline Insights, 2020
The Interstitial Cystitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Interstitial Cystitis across the complete product development cycle, including all clinical and nonclinical stages.
Interstitial Cystitis – Market Insights, Epidemiology, and Market Forecast-2030
The Interstitial Cystitis market report provides current treatment practices, emerging drugs, Interstitial Cystitis market share of the individual therapies, current and forecasted Interstitial Cystitis market Size from 2017 to 2030 segmented by seven major markets.